Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6K | 156K | 9K | 0 | 124K |
| Gross Profit | -53K | 51K | -1K | 0 | -9K |
| Operating Income | -6M | -6M | -6M | -2M | -645K |
| EBITDA | -6M | -7M | -5M | -750 | 0 |
| Net Income | -6M | -7M | -5M | -2M | -651K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.173
+2.37% today
1Y Change
-77.25%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Virax Biolabs Group Limited (VRAX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.17 and down 77.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -96.0%, EPS growth of +41.7%, a dividend yield of 0.0%. What stands out right now is revenue -96.0%, EPS +41.7%, free cash flow +30.3% with operating margin -196566.7% and ROIC -99.8%. Valuation already assumes a fairly strong business story at price/sales 190.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VRAX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRAX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRAX Max Drawdown
-90.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRAX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$123.8K
FY Net Income
-$651.0K
+61.9% YoY
Free Cash Flow
-$590.2K
+27.1% YoY
Revenue Growth
-96.0%
EPS Growth
+41.7%
Gross Margin
-8774.5%
Net Margin
-189001.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6K | 156K | 9K | 0 | 124K |
| Gross Profit | -53K | 51K | -1K | 0 | -9K |
| Operating Income | -6M | -6M | -6M | -2M | -645K |
| EBITDA | -6M | -7M | -5M | -750 | 0 |
| Net Income | -6M | -7M | -5M | -2M | -651K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 4M | 9M | 22K | 18K |
| Total Assets | 6M | 5M | 10M | 49K | 94K |
| Total Liabilities | 965K | 345K | 908K | 1M | 871K |
| Shareholder Equity | 6M | 5M | 9M | -975K | -596K |
| Total Debt | 377K | 224K | 146K | 4K | 179K |
| Net Debt | -4M | -3M | -9M | -18K | 162K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
590K
+27.1% YoY
Capital Expenditures
0
Free Cash Flow
590K
+27.1% YoY
Key ratios
Gross Margin
-8774.5%
Operating Margin
-196566.7%
Net Margin
-189001.7%
ROE
-102.5%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.